STOCK TITAN

[Form 4] Iridex Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Iridex Corp (IRIX) Form 4: Chief Financial Officer Romeo Dizon reported two purchases on 08/21/2025 totaling 2,000 shares of common stock. The first purchase was 1,000 shares at $1.27 and the second was 1,000 shares at $1.22. Beneficial ownership increased to 46,745 shares following the transactions. The form was signed 08/22/2025 by an attorney-in-fact.

Iridex Corp (IRIX) Modulo 4: Il Chief Financial Officer Romeo Dizon ha comunicato due acquisti in data 21/08/2025 per un totale di 2.000 azioni ordinarie. Il primo acquisto è stato di 1.000 azioni a $1,27 e il secondo di 1.000 azioni a $1,22. La partecipazione detenuta è aumentata a 46.745 azioni dopo le operazioni. Il modulo è stato firmato il 22/08/2025 da un procuratore.

Iridex Corp (IRIX) Formulario 4: El director financiero Romeo Dizon informó dos compras el 21/08/2025 por un total de 2.000 acciones ordinarias. La primera compra fue de 1.000 acciones a $1,27 y la segunda de 1.000 acciones a $1,22. La participación beneficiaria aumentó a 46.745 acciones tras las transacciones. El formulario fue firmado el 22/08/2025 por un apoderado.

Iridex Corp (IRIX) Form 4: 최고재무책임자(Chief Financial Officer) 로미오 디존(Romeo Dizon)이 2025-08-21에 총 2,000주의 보통주를 매수했다고 보고했습니다. 첫 번째 매수는 1,000주를 주당 $1.27에, 두 번째 매수는 1,000주를 주당 $1.22에 이루어졌습니다. 거래 후 실질 소유주 지분은 46,745주로 증가했습니다. 해당 서류는 2025-08-22에 대리인(법정대리인)에 의해 서명되었습니다.

Iridex Corp (IRIX) Formulaire 4 : Le directeur financier Romeo Dizon a déclaré deux achats le 21/08/2025 pour un total de 2 000 actions ordinaires. Le premier achat portait sur 1 000 actions à 1,27 $ et le second sur 1 000 actions à 1,22 $. La participation bénéficiaire est passée à 46 745 actions après les opérations. Le formulaire a été signé le 22/08/2025 par un mandataire.

Iridex Corp (IRIX) Formular 4: Chief Financial Officer Romeo Dizon meldete am 21.08.2025 zwei Käufe von insgesamt 2.000 Stammaktien. Der erste Kauf umfasste 1.000 Aktien zu $1,27 und der zweite 1.000 Aktien zu $1,22. Das wirtschaftliche Eigentum stieg nach den Transaktionen auf 46.745 Aktien. Das Formular wurde am 22.08.2025 von einem Bevollmächtigten unterzeichnet.

Positive
  • Reporting person acquired 2,000 common shares (1,000 at $1.27 and 1,000 at $1.22) on 08/21/2025
  • Beneficial ownership updated to 46,745 shares following the reported transactions
  • Form includes required signature via attorney-in-fact dated 08/22/2025
Negative
  • None.

Insights

TL;DR: Insider purchases of 2,000 shares by the CFO were reported, with specific prices and updated beneficial ownership.

The Form 4 discloses two non-derivative purchases by Romeo Dizon on 08/21/2025: 1,000 shares at $1.27 and 1,000 shares at $1.22, bringing his reported beneficial ownership to 46,745 shares. Transactions are straightforward purchases (code P) and are properly documented with an attorney-in-fact signature dated 08/22/2025. No derivatives or other arrangements are reported.

TL;DR: Filing shows routine insider purchase disclosures by a named officer with required signature and dates.

The submission identifies Romeo Dizon as Chief Financial Officer and reports purchases executed on 08/21/2025. The Form 4 is filed by one reporting person and includes the reporting person’s address. The document contains required signatures and explanations fields, with no amendments indicated. There are no derivative transactions or additional disclosures in the filing.

Iridex Corp (IRIX) Modulo 4: Il Chief Financial Officer Romeo Dizon ha comunicato due acquisti in data 21/08/2025 per un totale di 2.000 azioni ordinarie. Il primo acquisto è stato di 1.000 azioni a $1,27 e il secondo di 1.000 azioni a $1,22. La partecipazione detenuta è aumentata a 46.745 azioni dopo le operazioni. Il modulo è stato firmato il 22/08/2025 da un procuratore.

Iridex Corp (IRIX) Formulario 4: El director financiero Romeo Dizon informó dos compras el 21/08/2025 por un total de 2.000 acciones ordinarias. La primera compra fue de 1.000 acciones a $1,27 y la segunda de 1.000 acciones a $1,22. La participación beneficiaria aumentó a 46.745 acciones tras las transacciones. El formulario fue firmado el 22/08/2025 por un apoderado.

Iridex Corp (IRIX) Form 4: 최고재무책임자(Chief Financial Officer) 로미오 디존(Romeo Dizon)이 2025-08-21에 총 2,000주의 보통주를 매수했다고 보고했습니다. 첫 번째 매수는 1,000주를 주당 $1.27에, 두 번째 매수는 1,000주를 주당 $1.22에 이루어졌습니다. 거래 후 실질 소유주 지분은 46,745주로 증가했습니다. 해당 서류는 2025-08-22에 대리인(법정대리인)에 의해 서명되었습니다.

Iridex Corp (IRIX) Formulaire 4 : Le directeur financier Romeo Dizon a déclaré deux achats le 21/08/2025 pour un total de 2 000 actions ordinaires. Le premier achat portait sur 1 000 actions à 1,27 $ et le second sur 1 000 actions à 1,22 $. La participation bénéficiaire est passée à 46 745 actions après les opérations. Le formulaire a été signé le 22/08/2025 par un mandataire.

Iridex Corp (IRIX) Formular 4: Chief Financial Officer Romeo Dizon meldete am 21.08.2025 zwei Käufe von insgesamt 2.000 Stammaktien. Der erste Kauf umfasste 1.000 Aktien zu $1,27 und der zweite 1.000 Aktien zu $1,22. Das wirtschaftliche Eigentum stieg nach den Transaktionen auf 46.745 Aktien. Das Formular wurde am 22.08.2025 von einem Bevollmächtigten unterzeichnet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dizon Romeo R

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/21/2025 P 1,000 A $1.27 45,745 D
Common Stock 08/21/2025 P 1,000 A $1.22 46,745 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Nilo De Castro, Attorney-in-fact for Romeo Dizon 08/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did IRIX CFO Romeo Dizon report on the Form 4?

He reported two purchases on 08/21/2025: 1,000 shares at $1.27 and 1,000 shares at $1.22.

How many shares does Romeo Dizon beneficially own after the reported trades?

46,745 shares of Iridex Corp common stock following the transactions.

What type of filing was submitted for IRIX and who signed it?

Form 4 was filed reporting insider changes and was signed by an attorney-in-fact, Nilo De Castro, on 08/22/2025.

Were any derivative securities reported in this Form 4 for IRIX?

No derivatives are reported; Table II contains no entries for derivative securities.

Was the Form 4 filed by multiple reporting persons?

No; the form indicates it was filed by one reporting person.
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

21.75M
12.26M
27.57%
15.83%
1.68%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW